Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis [0.03%]
灯塔计划——支持国家、区域和全球层面的决策以消除病毒性肝炎
Homie Razavi
Homie Razavi
Background: Tools to eliminate Hepatitis B and C have been available and in 2016, the World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis. However, the adoption of hepatitis elimination programs has remained...
William A Lee,Andrew K Cheng
William A Lee
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that repl...
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis [0.03%]
应用替诺福韦基药物开展预防以推进艾滋病防控工作
Salim S Abdool Karim,Cheryl Baxter,Quarraisha Abdool Karim
Salim S Abdool Karim
Tenofovir-based pre-exposure prophylaxis (PrEP) revolutionized the global HIV prevention landscape. Prior to the proof-of concept trial in 2010, which demonstrated that tenofovir (TFV) could prevent sexual transmission of HIV, prevention op...
The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B [0.03%]
富马酸替诺福韦二吡美司在预防乙肝垂直传播中的作用
Calvin Q Pan
Calvin Q Pan
Background: Since immunoprophylaxis failure can occur if maternal serum hepatitis B virus (HBV) DNA levels are >200,000 IU/ml, tenofovir disoproxil fumarate (TDF) therapy has been investigated for preventing mother to chi...
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19 [0.03%]
从抑制丙型肝炎病毒到治疗新型冠状病毒肺炎瑞德西韦的历程
Tomas Cihlar,Richard L Mackman
Tomas Cihlar
If a planned path reaches a dead-end, one can simply stop. Or one can turn around, walk back to the last intersection and take another path, or one can consider taking few paths in parallel. The last scenario is reflective of the journey of...
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection [0.03%]
论著评论：先天性巨细胞病毒感染的治疗药物研发进展
Richard J Whitley
Richard J Whitley
In the mid 1980's, I flew from Birmingham, Alabama to San Francisco, rented a car, and drove to Palo Alto so that I could meet with John Martin at Syntex. John, along with Julian Verheyden, synthesized ganciclovir, which had significant in ...
Madhu C Choudhary,John W Mellors
Madhu C Choudhary
A co-formulated, one pill once a day antiretroviral regimen (single-tablet regimen), containing efavirenz, emtricitabine, and tenofovir disoproxyl fumarate (Atripla), revolutionized the antiretroviral therapy landscape. Single-tablet regime...
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case [0.03%]
在发展中国家提供高质量低成本的药品与全球政府和仿制药品生产商合作-一个商业案例分析
Gregg Alton,Clifford Samuel,Anand Reddi
Gregg Alton
Background: Gilead Sciences, under Dr. John Martin's leadership, created its Global Access Program to deliver high-quality, affordable medicines to treat and ultimately eliminate some of the world's most challenging-to-tr...
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir [0.03%]
最佳的艾滋病预防、治疗和清除骨架药物：恩曲他滨+替诺福韦
Raymond F Schinazi,Dharmeshkumar Patel,Maryam Ehteshami
Raymond F Schinazi
The advent of antiretroviral combination therapy has significantly impacted the HIV/AIDS epidemic. No longer a death sentence, HIV infection can be controlled and suppressed using cocktail therapies that contain two or more small molecule d...
The making of the one pill-Developing single tablet regimens for HIV and for HCV [0.03%]
一-pill的诞生——艾滋病和丙肝单片疗法的研发历程
Taiyin Yang,Reza Oliyai,Kenneth M Kent
Taiyin Yang
A concept of "all or nothing" inspired the innovation of a one-pill-once-daily HIV treatment. Atripla® was the one pill that combined efavirenz, emtricitabine, and tenofovir disoproxil fumarate to become the first daily single tablet regim...